Please login to the form below

Not currently logged in
Email:
Password:

Valeant acquires GSK's Zovirax

Valeant Pharmaceuticals' Biovail Laboratories has signed a deal under which it will acquire all US and Canadian rights to certain formulations of GSK's Zovirax

Valeant Pharmaceuticals' Biovail Laboratories has signed a deal under which it will acquire all US and Canadian rights to non-ophthalmic topical formulations of GlaxoSmithKline's (GSK) herpes drug Zovirax (acyclovir) for $300m.

Biovail was already the exclusive distributor of the product in the US, where the deal will allow the company to keep more of the profits from the drug. Biovail did not previously have rights to the drug in Canada.

"The current distribution agreement between GSK and Biovail was problematic for both companies and this new arrangement should solve this issue for both organisations,” Valeant CEO J Michael Pearson said in a statement.  "We believe that our sales and marketing organisations in the United States and Canada have the ability to revitalise and grow the brand."

Zovirax ointment and cream are indicated for genital herpes and cold sores. Biovail paid $133m for the marketing rights to the topical formulations of Zovirax in a ten-year deal signed between the companies in 2001. In late 2002, Biovail announced that it had extended its existing 10-year agreement with GSK for the marketing rights to 20 years for an additional payment of $40m.

4th February 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics